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Introduction
Since December 2019, a novel coronavirus designated 
as severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) emerged in the city of Wuhan, China, and 
spread rapidly over the boundaries to cause the pandemic 
of viral pneumonia (so-called novel coronavirus disease 
or COVID-19) in just three months (Burki, 2020; Dewi 
et al., 2020). The ultra-rapid expansion of the coronavirus 
has prompted the authorities to find quick and efficient 
solutions for the ensuing issues. One of these issues is the 
negative impacts of the viral pandemic on the common 
oncology practice, which has prompted the community 
oncologists to search for approaches to maintain their 
practices while improving the quality of care for patients 
(Kumar et al., 2020; Poonia et al., 2020; Yadav et al., 
2020b). In this regard, experts from all over the world 
have presented international and national guidelines to 
cope with the crisis and to provide adjusted care (Ameri 
et al., 2020a; Ameri et al., 2020b; Dabkara et al., 2020; 
Miltiadou et al., 2020; Mousavi et al., 2020; Prajoko and 
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Supit, 2020; Rakhsha et al., 2020a; Rakhsha et al., 2020b; 
Shankar, 2020; Shankar et al., 2020; Siavashpour et al., 
2020; Singh et al., 2020; Taghizadeh-Hesary and Akbari, 
2020). Oncology centers can follow the guidelines to 
develop the standards of practices. However, the clinical 
decision in the midst of the COVID-19 era is not the 
only case, and it might be overshadowed by several other 
factors. This review provides a comprehensive look over 
the main impacts of COVID-19 on oncology practices 
and how to tackle them. 
Impacts and Resolutions
Early studies reported that chemotherapy within 
the past four weeks slightly increases the mortality 
of COVID-19 (Yang et al., 2020), however, further 
cohort studies showed no significant effect of recent 
anticancer therapies (including radiotherapy, cytotoxic 
chemotherapy, endocrine therapy, or immunotherapy) 
on the COVID-19 mortality (Kuderer et al., 2020; Lee 
et al., 2020; Vuagnat et al., 2020). In addition, a recent 
meta-analysis clearly shows that a four-week delay in 
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cancer treatment is associated with a 10% increased risk 
of death across all common cancers (Hanna et al., 2020b). 
Going by these findings, it would be ideally expected not 
to modify the treatment of cancer over the pandemic; 
however, the following shortcomings would make this 
objective far beyond our wildest dreams. 
1.1. Impact on Health care Providers 
The COVID-19 pandemic has resulted in a huge 
burden on the health system for its easy transmission and 
high mortality rate (Okell et al., 2020). Epidemiological 
studies have revealed that the rate of hospitalization, 
intensive care unit (ICU) admission, and case fatality rate 
of patients with COVID-19 are approximately 20%, 9%, 
and 3.3%, respectively (Almasi-Hashiani et al., 2020; 
Basu, 2020). The health infrastructure is further influenced 
by the fact that health care providers (HCPs) constitute 
up to 11% of COVID-19 cases (Jeremias et al., 2020). 
In addition, re-deployment of staff towards critical care 
to manage patients with COVID-19 further influences 
cancer care. A weakened health system – with priorities 
shifting to manage the viral pandemic – will have short- 
and long-term impacts on the preventive, diagnostic, and 
therapeutic management of cancer. 
1.2. Resolutions
HCPs are crucial to any health-care system; therefore, 
policymakers have to enact strategies to support exposed 
and infected HCPs over the pandemic. These strategies 
are classified into risk stratification, preventive measures, 
active clinical monitoring, easy access to diagnostic 
tests, and relevant decision on removal from and return 
to work. In this context, the HCPs of oncology wards are 
considered high-risk and they need effective personal 
protective equipment (PPE), screening with symptoms 
as well as SARS-CoV-2 diagnostic tests, application 
of standard isolation duration, and effective treatments 
(Bielicki et al., 2020). 
2.1. Impact on Medical Equipment
During the pandemic, health-care facilities are 
confronted with engagement of medical equipment with 
huge number of patients with probable or confirmed 
COVID-19 that may negatively affect cancer care. 
This issue may involve all types of medical equipment, 
including diagnostic (e.g., medical imaging machines and 
medical laboratory equipment), therapeutic (e.g., linear 
accelerators), and life supportive (e.g., medical ventilators) 
equipment. Medical centers may also encounter shortage 
of hospital beds that subsequently will impair inpatient 
cancer care. In addition, the necessity of cleaning and 
disinfecting of medical equipment further limits their 
application for coronavirus-non-infected patients (e.g., 
cancer patients) to specified time limits. 
2.2. Resolutions
Health-care facilities can manage this issue by 
allocating a proportion of the number or the time of their 
equipment to the patients with COVID-19. The latter 
would be readily available by assigning coronavirus-non-
infected patients to one end of the day, preferably in the 
morning after last night cleaning and disinfection of the 
devices and environment (Rezaei et al., 2020). 
3.1. Impact on Access to Medications
Drug shortage is an ongoing challenge for cancer 
centers in a time of crisis. This issue is mainly due to 
budget allocation to provide the necessary medication 
for the management of COVID-19 and its complications. 
The cancer drug shortage may have major negative 
impacts on patients’ survival (e.g., chemotherapeutics 
in the adjuvant setting or colony-stimulating factors in 
case of fever and neutropenia) or quality of life (e.g., 
narcotics or antiemetics). In an analysis of cancer centers 
from 54 countries, 9.83% (of total 356 centers) have 
confirmed drug shortage during the pandemic (Ventola, 
2011). Even in a nonepidemic situation, intravenous 
cancer drugs topped the list of medication shortages 
(Barlas, 2011). This might be due to the fact that these 
medications are more vulnerable to Good Manufacturing 
Practice (GMP) violations issued by the world health 
organization (WHO-GMP), U.S. Food and Drug 
Administration (CGMP), or European Union (EU-GMP) 
(Ventola, 2011). In addition, increased procurement 
time, scarcity of alternative providers, supply chain 
interruptions, and delays in delivery times may further 
impair access to biological and chemical oncology drugs 
over pandemic.
3.2. Resolutions
The management of drug shortages is complicated over 
the viral pandemic, especially in the oncology domain. 
The specific situation of oncology –that necessitates the 
provision of medications without interruption– requires 
advanced strategies to deal with the issue. In 2018, 
the American Society of Health-System Pharmacists 
(ASHP) provided recommendations for managing drug 
shortages, including (1) formation of a working group, 
(2) validation of drug shortage, (3) formation of resource 
allocation committee, (4) patient prioritization, (5) finding 
and approving alternative medications or therapeutic 
equivalents, and (6) addressing ethical consideration 
for alternative choices (Fox and McLaughlin, 2018). 
By following this guideline, health-care facilities can 
mitigate the impact of the viral pandemic on the provision 
of necessary medications and reduce its adverse effects 
on patient care. 
4.1. Impact on Treatment Approaches
As the COVID-19 pandemic worsens, health care 
delivery has been tremendously modified in all disciplines, 
including oncology. The immunosuppressive nature of 
cancer treatments has put the oncologists in the great 
pressure to make the difficult decision of the best care over 
the pandemic, which would not compromise the patients’ 
quality and quantity of life (Haghighat and Dehghani, 
2020; Mishra et al., 2020). 
4.2. Resolutions
In the current unprecedented situation, the approaches 
settled by health-care facilities to manage the challenge 
fall into three categories. First, for survivorship and 
surveillance visits, oncologists can remotely visit 
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authorities must try to improve public awareness on the 
risks of not seeking timely medical care for their warning 
symptoms suggesting malignancy (Maringe et al., 2020). 
Third, local health-care authorities need to provide the 
resources to meet the existing and projected needs of 
cancer care over the not so short COVID-19 era.  
6.1. Impact on patients Accommodation
The accommodation is a necessity for patients who 
traveling away from their homes to get the best cancer 
care. Over the viral pandemic, however, this may be 
compromised by assigning the existing premises to 
patients with COVID-19 and making patients with cancer 
face extra emotional and financial burden. 
6.2. Resolutions
To solve this problem, policymakers in concert with 
charity organizations can help health-care facilities to 
provide specified free places for the accommodation of 
patients with cancer during their treatment. In addition 
to the lodging of patients, testing of SARS-CoV-2 prior 
to accommodation, allocation of private rooms to cancer 
patients and their caregivers, using appropriate air 
conditioning systems (Rezaei et al., 2020), and paying 
special attention to the guest services (e.g. food and 
beverage, cleaning, etc.) and interactions with staff and 
other patients are crucial to decrease viral transmission 
in the premises.  
7.1. Impact on Patients’ Psychological Health
The emotional threats of the COVID-19 pandemic 
have been affecting people all over the world, particularly 
patients with cancer. In this context, cancer patients are 
vulnerable to a variety of psychological threats, such as 
anxiety, depression, and cognitive disorders that would 
adversely affect their quality of life and can induce 
the onset of symptoms (Adams et al., 2018; Swainston 
et al., 2020). This critical issue might be initiated by 
quarantine and lockdown situations –that increase their 
social isolation and loneliness– and disruption of cancer 
treatment services (as explained in section 1-6) resulting 
in exacerbation of patients’ emotional distress.   
7.2. Resolutions
The adverse effects of the COVID-19 outbreak on 
cancer patients’ emotional and cognitive health should not 
be ignored. With the aforementioned concerns in mind, 
experts propose to (1) maintain interpersonal relationships 
–that has powerful therapeutic effects on patients’ 
emotional health during the hospitalization, quarantine, or 
lockdown situations– through several ways (e.g. by phone 
or video calls with family members, psychological support 
with health care providers, etc.) (Garutti et al., 2020; 
Passchier et al., 2020); (2) apply telemedicine to decrease 
patients’ concern over the quarantine (or lockdown) 
situation regarding the treatment toxicities, follow up 
evaluation, along with others; (3) give reassurance 
to the patients to relieve their negative thoughts (e.g. 
misplaced worries over negative effect of cancer treatment 
on COVID-19 mortality) and to encourage treatment 
compliance (Garutti et al., 2020; Lee et al., 2020); (4) 
patients using telephone calls or video applications. This 
practice may also include patients who are receiving 
cancer treatments with low-risk toxicity profile. Second, 
in cases who the survival benefit of cancer therapy is 
minimal, oncologists may choose the best supportive care 
instead. In the remaining patients that treatment is more 
beneficial, oncologists can apply myriads of modifications 
to the treatment to minimize hospital visits and decrease 
patients’ exposure in the medical facilities. Examples 
would include, hypofractionated radiotherapy instead 
of conventional schedules, chemotherapy regimen with 
fewer cycles, less toxic chemotherapy regimens, and 
using oral rather than parenteral medications (Haresh 
et al., 2020; Rakhsha et al., 2020a; Schrag et al., 2020). 
Although several studies declared that cancer therapy in 
several specified cases (e.g. many prostate cancers, many 
neuroendocrine tumors, some central nervous system 
tumors, some thyroid cancers, and some lymphomas) can 
safely be postponed for 8 to 12 weeks (Schrag et al., 2020), 
the recent meta-analyses demonstrated opposite findings 
for several other malignancies (including head and neck, 
bladder, breast, lung, colorectal, and cervical cancers). 
In the latter group, minimizing delays to treatment is 
essential to improve cancer survival rates (Hanna et al., 
2020b). Overall, oncologists need to assess the pros and 
cons of cancer treatment over the pandemic on a case-
by-case basis. 
5.1. Impact on Patients Referral 
As COVID-19 emerged, patients’ referral to the 
oncology centers has been halted for several reasons. First, 
clinicians may opt to defer the nonemergency surgeries 
(including elective cancer surgeries) due to low hospital/
ICU bed capacity, shortage of ventilators, limited supplies 
of PPE, and risk of nosocomial coronavirus transmission. 
On the other hand, opponents believe that the deferring 
of elective cancer surgeries has adverse impacts on 
patients’ survival (Hanna et al., 2020b). Second, the 
pandemic may also suspend the screening programs in an 
overwhelmed health care system, which is associated with 
a higher rate of cases with advanced stage at diagnosis 
and worse prognosis in the future (Maringe et al., 2020). 
Third, patients’ anxieties –concerning risk of infection 
with coronavirus– can also impact their health-seeking 
behavior and impedes their referral for cancer screening or 
following up a recent clinical symptom. Last but not least, 
the lockdown situation can further impair the patients’ 
referral by preventing inter-city travels of patients seeking 
the best cancer care. 
5.2. Resolutions
To counteract this issue, health-care facilities can take 
several measures. First, providing rapid and accurate 
COVID-19 testing before surgery and diagnostic services 
(e.g., screening colonoscopy, mammography, etc.), 
assigning dedicated operating rooms and screening 
clinics with dedicated staff, and guaranteeing sufficient 
availability of PPE for staff and patients to decrease the 
concerns of viral transmission and sustain the surgical and 
screening care over the pandemic. Second, To mitigate the 
additional cancer deaths resulting from delayed diagnosis, 
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reduce the period of quarantine and lockdown situations 
by authorities; and (5) follow the solutions explained in 
sections 1-6 to decrease the probability and duration of 
treatment disruption and patients’ anxiety.  
8.1. Impact on Cancer Research
Any of the restrictions explained in the preceding 
sections can negatively affect the cancer clinical 
researches by impeding patients’ accrual to the clinical 
trials and obtaining biospecimens (Singh and Prasad, 
2020). In response to the viral pandemic, many cancer 
centers have transformed their field of interest to 
COVID-19-directed studies. This change is also evident 
for a large percentage of oncology journals by allocating 
numerous special issues to the COVID-19 subject and 
putting the review process of the articles about COVID-19 
in priority.
8.2. Resolutions
In response to the COVID-19 crisis, research and 
therapeutic communities around the world are united to 
provide and share guidelines. To that end, the European 
Society of Medical Oncology (ESMO) has provided free 
online accessible protocols on how to maintain cancer 
care over the viral pandemic. In addition, oncologists 
have published their own experiences on the management 
of site-specific malignancies to provide a guide for 
their colleagues in the pandemic situation (Dietz et al., 
2020; Guckenberger et al., 2020; Hanna et al., 2020a; 
Siavashpour et al., 2020; Thomson et al., 2020; Zaorsky 
et al., 2020). Also, several oncologists have opted to apply 
their experiences in the treatment of cancer toward the 
management of COVID-19; for example, use of low-dose 
whole-lung radiotherapy in the treatment of COVID-19 
pneumonia (Ameri et al., 2020a; Ameri et al., 2020b; 
Hess et al., 2020). 
In the midst of the COVID-19 pandemic, a number 
of main cancer research centers have decided to continue 
their trials considering specific preparations. For instance, 
(1) in Dana-Farber Cancer Institute in Boston, researchers 
have tried to decrease the patient-staff exposures by using 
phone or video calls to follow up their patients remotely; 
(2) the researchers of the University of Arizona Cancer 
Center have applied similar approach and have limited 
their trials to those that are potentially life-prolonging. 
They also prescreen the patients via telephone calls 
for COVID-19 symptoms and recent exposure history 
before visits; (3) in the Perlmutter Cancer Center in New 
York, researchers have stratified the trials in order that 
putting phase 2 or 3 clinical trials in priority and halting 
early-phase ones. In addition, they have restricted the 
trials to the outpatient setting; and (4) the researchers of 
the Yale Cancer Center in New Haven, have followed a 
similar strategy by continuing ongoing trials and halting 
new ones (Ribas and Leng, 2020). 
9.1. Impact on Cancer Multidisciplinary Team Meetings 
The multidisciplinary team meetings (MDTM) in 
oncology are held to provide the best evidence-based 
care for patients in terms of diagnosis, treatment, and 
survivorship. As such, the literature demonstrates the 
survival improvement with the MDTM approach to cancer 
care (Kung and Tsai, 2014; Dharmarajan et al., 2020). 
The COVID-19 pandemic, however, has complicated 
to hold in-person MDTM due to the possibility of viral 
transmission (Yadav et al., 2020a).
9.2. Resolutions
Prior experience with virtual multidisciplinary team 
conferences (MDTC) has assisted the clinicians to 
overcome the shortcoming of in-person MDTM over 
the COVID-19 pandemic. The utilization of virtual 
MDTC is associated with decreased delays in cancer 
care (Stevenson et al., 2013; Salami et al., 2015), more 
convenient referral coordination (Billingsley et al., 2002), 
decreased travel burden (Stevenson et al., 2013), and the 
possibility to hold more frequent sessions (Salami et al., 
2015).
10.1. Economic Impacts 
The complications addressed in the previous sections 
may cause either decrease in the total income of cancer 
centers (due to reduced number of treated patients) or an 
increase in expenditures (e.g. by providing PPE for staff 
and patients) that eventually result in a negative financial 
balance of cancer centers during the viral pandemic 
(Yoshino et al., 2020). This issue may lead to a vicious 
cycle by disrupting the issues that are essential for cancer 
centers to continue serving; for instance, the periodic 
and preventive maintenance and ad-hoc repair of the 
radiotherapy equipment, the provision of medications, 
along with others.  
10.2. Resolutions
The governments and charity organizations must 
provide support to help medical institutions (including 
cancer centers) tide over the harsh economic condition 
over the COVID-19 era. 
In conclusion, during the COVID-19 era, the health 
system has to look beyond controlling the pandemic to 
effectively respond to all the health requirements of the 
general population, including cancer care. Toward this 
end, the current review article provides a step in that 
direction by highlighting ten main issues of cancer care 
during the viral pandemic. To solve these challenges and 
maintain cancer patients’ quality and quality of life, the 
health communities require concerted cooperation of 
other organizations, including government and charities. 
On a positive note, the solutions –given in the preceding 
sections– to improve the standards of cancer care over 
the pandemic can be a practical paradigm for possible 
future crises.
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